US 12,433,545 B2
Method, system and computer readable medium for assessing actionable glycemic risk
Stephen D. Patek, Charlottesville, VA (US)
Assigned to UNIVERSITY OF VIRGINIA PATENT FOUNDATION, Charlottesville, VA (US)
Filed by University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed on Jan. 23, 2020, as Appl. No. 16/750,184.
Application 16/750,184 is a continuation of application No. 15/551,503, granted, now 10,638,981, previously published as PCT/US2016/018027, filed on Feb. 16, 2016.
Claims priority of provisional application 62/116,791, filed on Feb. 16, 2015.
Prior Publication US 2020/0178905 A1, Jun. 11, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61M 5/172 (2006.01); G06F 17/12 (2006.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/30 (2018.01)
CPC A61B 5/7275 (2013.01) [A61B 5/14532 (2013.01); A61B 5/4839 (2013.01); A61B 5/7225 (2013.01); A61M 5/1723 (2013.01); G16H 20/17 (2018.01); G16H 50/30 (2018.01); A61M 2205/3584 (2013.01); G06F 17/12 (2013.01); G16H 40/63 (2018.01)] 27 Claims
OG exemplary drawing
 
1. A method for assessing actionable glycemic risk comprising:
obtaining an output glucose monitoring signal at a time t, the output glucose monitoring signal including a measure of blood glucose (BG);
determining a glycemic cost signal at the time t based on the output glucose monitoring signal with a glycemic cost function (J(BG)) algorithm that penalizes output glucose monitoring signals below a lower end point target (BGtarget,lo) and penalizes output glucose monitoring signals above an upper end point target (BGtarget,hi), wherein a blood glucose target range is defined by (BGtarget,lo) and (BGtarget,hi);
using the glycemic cost signal to quantify actionable risk and unaddressable risk, wherein actionable risk includes any one or combination of actionable hypoglycemia risk or actionable hyperglycemia risk;
determining the actionable risk at time-of-day s to generate any one or combination of a hypoglycemia risk profile (lop(s)) or a hyperglycemia risk profile (hip(s)) for influencing, monitoring, or administering insulin to a patient; and
generating a command signal that when received by an insulin delivery device will cause the insulin delivery device to administer insulin based on the hypoglycemia risk profile (lop(s)) and/or the hyperglycemia risk profile (hip(s).